BioNTech

BioNTech SE has agreed to acquire the British artificial intelligence (AI) startup InstaDeep for up to 562 million pounds ($682 million) to speed up its biotech research beyond COVID shots.

Victoza

The American Academy of Pediatrics (AAP) on Monday recommended use of weight-loss drugs in children ages 12 years or older for treatment of obesity, which impacts about 14.4 million kids and adolescents in the United States and can lead to serious health complications.

Ocugen Inc. said on Monday the COVID-19 vaccine developed by its Indian partner Bharat Biotech International Ltd. met the main goals of a trial in the United States.

COVID vaccination

The Omicron-adapted COVID-19 vaccine booster developed by Pfizer Inc. and BioNTech SE sharply reduced hospitalizations among older patients, Israeli researchers said on Monday, in some of the first evidence of the jab’s real-world effectiveness.

Pfizer

China is in talks with Pfizer Inc. to secure a license that will allow domestic drugmakers to manufacture and distribute a generic version of the U.S. firm’s COVID-19 antiviral drug Paxlovid in China, three sources told Reuters.

Baxter Renal Care

Baxter International Inc. said on Friday it plans to spin off its kidney care units, becoming the latest medical device maker to slim down in the face of supply-chain challenges.

Janssen

On Thursday, Fate Therapeutics announced it terminated a 2020 collaboration agreement with Johnson & Johnson’s biopharma subsidiary Janssen. In response, the next-generation cell therapy company’s stock sank by 54% in pre-market trading Friday. 

Amgen headquarters

Biotech behemoth Amgen inked a licensing agreement Thursday with Netherlands-based Synaffix for the development of next-generation antibody-drug conjugates. 

Moderna

Moderna entered into a collaboration/licensing agreement Thursday with oncology-focused CytomX to discover and develop conditionally activated mRNA therapies for cancer. 

Germany’s CureVac AG said on Friday its second-generation COVID-19 vaccine produced virus-neutralizing antibodies against the BA.1 subvariant of Omicron, based on preliminary data from an early-stage trial.